Aligos Therapeutics Inc. has disclosed programmed cell death protein 1 (PD-1; PDCD1; CD279), PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of hepatocellular carcinoma and hepatitis B virus (HBV).
